BioRadar® combines broad pathogen detection with quantitative monitoring and AI analysis to guide treatment decisions. From identifying pathogens to tracking change, it connects diagnosis with care — Diagno‑Care.
Knowing which pathogens are present is only part of the picture. BioRadar® also measures their levels and tracks changes over time, giving clinicians clearer information throughout treatment.
BioRadar® brings sample preparation, amplification, detection, and quantitative analysis into one platform.
A broad panel brings pneumonia pathogens and resistance markers together in one test, helping clinicians see a complete picture of infection.
We have used human samples throughout BioRadar® development. This has reduced development risk, built confidence in the platform, and established a strong foundation for clinical investigation.
In the international EPIC III study, 30% of ICU patients with suspected or proven infection died in hospital. We are starting with ICU pneumonia, where rapid pathogen identification and quantitative monitoring address an urgent need. Our goal is to turn better information into faster treatment decisions and more lives saved.
Our development pipeline spans respiratory disease, critical infections, oncology, blood safety, environmental monitoring, and outbreak surveillance.
Founded in Hong Kong in 1999, HKLife brings decades of molecular diagnostics experience to BioRadar®, from assay research and outbreak response to product development.
Interested in BioRadar®, investment, or collaboration? Contact our team to learn more.